Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Isoniazid

FDA-approved product (tablet, oral), marketed as Dow-Isoniazid, Hyzyd, Inh and 5 more.

Registered studies
50+
Lab records
268
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Isoniazid
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • Pulmonary tuberculosis
  • Silicosis
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Hydrazides
FDA pharmacologic class
Antimycobacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AC01; WHO ATC J04AC51; FDA class Antimycobacterial

Repurposing investigation

Isoniazid is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA8.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli7.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae3.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 241 of 268 lab records
Open Isoniazid in ChEMBL Registered studies below
Show the latest 150 of 268 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Isoniazid with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of Diabetes Control and Effect on Transmission and Development of Tuberculosis

    NCT03498534 · start 2012-09

    Registered record
    Registry ID
    NCT03498534
    Conditions
    Latent Tuberculosis; Diabetes Mellitus
    Interventions
    Isoniazid 300Mg Tab; Isoniazid 300 MG; Isoniazid 300 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2012-09
    Completion
    2013-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLatent Tuberculosis; Diabetes Mellitus
    InterventionIsoniazid 300Mg Tab; Isoniazid 300 MG; Isoniazid 300 MG
    PhasePhase 4
    Registry statusWithdrawn

  • Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)

    NCT01404312 · start 2012-05-23

    Registered record
    Registry ID
    NCT01404312
    Conditions
    Tuberculosis; HIV Infections
    Interventions
    Rifapentine (RPT); Isoniazid (INH); Pyridoxine (Vitamin B6)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-05-23
    Completion
    2017-11-14
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; HIV Infections
    InterventionRifapentine (RPT); Isoniazid (INH); Pyridoxine (Vitamin B6)
    PhasePhase 3
    Registry statusCompleted

  • "Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients".

    NCT01761201 · start 2012-01

    Registered record
    Registry ID
    NCT01761201
    Conditions
    Latent Tuberculosis Infection; Infection in Solid Organ Transplant Recipients
    Interventions
    Levofloxacin; Isoniazid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2012-01
    Completion
    2014-02
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLatent Tuberculosis Infection; Infection in Solid Organ Transplant Recipients
    InterventionLevofloxacin; Isoniazid
    PhasePhase 3
    Registry statusTerminated

  • A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin, Isoniazid, Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy Adults

    NCT01399788 · start 2011-07

    Registered record
    Registry ID
    NCT01399788
    Conditions
    Healthy Volunteers
    Interventions
    Myrin P Forte; Single drug references
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-07
    Completion
    2011-08
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionMyrin P Forte; Single drug references
    PhasePhase 1
    Registry statusCompleted

  • Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination (Rifampicin+Isoniazid, Myrin© 2) And The Reference Drug (Rifampicin, Rimactane®)

    NCT01311505 · start 2011-04

    Registered record
    Registry ID
    NCT01311505
    Conditions
    Tuberculosis
    Interventions
    Myrin© 2 (Rifampicin + Isoniazid); Rimactane® (Rifampicin)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-04
    Completion
    2011-05
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionMyrin© 2 (Rifampicin + Isoniazid); Rimactane® (Rifampicin)
    PhasePhase 1
    Registry statusCompleted

  • Study of Rifampicin in Multiple System Atrophy

    NCT01287221 · start 2011-03

    Registered record
    Registry ID
    NCT01287221
    Conditions
    Multiple System Atrophy
    Interventions
    Rifampicin; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2011-03
    Completion
    2013-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple System Atrophy
    InterventionRifampicin; placebo
    PhasePhase 3
    Registry statusTerminated

  • Anti-tuberculosis (TB) Drug Levels and Correlation With Drug Induced Hepatotoxicity

    NCT01456845 · start 2010-08

    Registered record
    Registry ID
    NCT01456845
    Conditions
    Hepatitis; Tuberculosis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-08
    Completion
    2012-06
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis; Tuberculosis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection

    NCT01136161 · start 2010-06

    Registered record
    Registry ID
    NCT01136161
    Conditions
    Latent Tuberculosis Infection; Tuberculosis
    Interventions
    RUTI; RUTI; RUTI; RUTI Matching Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-06
    Completion
    2011-05
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLatent Tuberculosis Infection; Tuberculosis
    InterventionRUTI; RUTI; RUTI; RUTI Matching Placebo
    PhasePhase 2
    Registry statusCompleted

  • Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis

    NCT00728507 · start 2009-11

    Registered record
    Registry ID
    NCT00728507
    Conditions
    Tuberculosis
    Interventions
    Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid; Isoniazid, Rifampin, Pyrazinamide, Ethambutol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-11
    Completion
    2013-04
    Enrolment
    121

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifapentine, Moxifloxacin, Pyrazinamide, Isoniazid; Isoniazid, Rifampin, Pyrazinamide, Ethambutol
    PhasePhase 2
    Registry statusTerminated

  • A Bioequivalence Study of Two Different Dosages of Isoniazid Tablet Formulations in Human Healthy Volunteers

    NCT02043314 · start 2008-10

    Registered record
    Registry ID
    NCT02043314
    Conditions
    Tuberculosis
    Interventions
    Isoniazida
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-10
    Completion
    2009-03
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionIsoniazida
    PhasePhase 1
    Registry statusCompleted

  • Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)

    NCT00495651 · start 2008-03

    Registered record
    Registry ID
    NCT00495651
    Conditions
    HIV Infections; Tuberculosis
    Interventions
    Antiretroviral medications; Antiretroviral medications+Isoniazid prophylaxis; Antiretroviral medications; Antiretroviral medications+Isoniazid prophylaxis
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-03
    Completion
    2015-01
    Enrolment
    2,073

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Tuberculosis
    InterventionAntiretroviral medications; Antiretroviral medications+Isoniazid prophylaxis; Antiretroviral medications; Antiretroviral medications+Isoniazid prophylaxis
    PhasePhase 3
    Registry statusCompleted

  • Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment

    NCT00737724 · start 2008-03

    Registered record
    Registry ID
    NCT00737724
    Conditions
    HIV; AIDS; Tuberculosis
    Interventions
    Simultaneous ARV and antiMTB; Deferred RV and antiMTB treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2008-03
    Completion
    2011-02
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; AIDS; Tuberculosis
    InterventionSimultaneous ARV and antiMTB; Deferred RV and antiMTB treatment
    PhaseNot applicable
    Registry statusTerminated

  • Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO)

    NCT00495326 · start 2007-12

    Registered record
    Registry ID
    NCT00495326
    Conditions
    Tuberculosis; Aids; Hiv Infections
    Interventions
    Nevirapine based therapy; Efavirenz based therapy; Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2007-12
    Completion
    2011-04
    Enrolment
    570

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Aids; Hiv Infections
    InterventionNevirapine based therapy; Efavirenz based therapy; Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT)

    NCT00298870 · start 2005-06

    Registered record
    Registry ID
    NCT00298870
    Conditions
    Pulmonary Tuberculosis
    Interventions
    Isoniazid; isoniazed
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-06
    Completion
    Not recorded
    Enrolment
    172

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionIsoniazid; isoniazed
    PhasePhase 4
    Registry statusCompleted

  • Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis

    NCT00396084 · start 2004-02-10

    Registered record
    Registry ID
    NCT00396084
    Conditions
    Tuberculosis
    Interventions
    Gatifloxacin; Isoniazid; Levofloxacin; Linezolid; Moxifloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2004-02-10
    Completion
    2007-12-28
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionGatifloxacin; Isoniazid; Levofloxacin; Linezolid +1 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted